ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of i
March 19, 2018H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics BV (Prexton) today announced signing of a definitive agreement in which Lundbeck will acquire Prexton -
Lundbeck Acquires Prexton Therapeutics
March 19, 2018Denmark-based H. Lundbeck A/S dropped €100 million in upfront money, or about $123 million, to acquire Prexton Therapeutics, a 2012 spinout from Merck KGaA, and its Phase II treatment for Parkinson’s disease.
Pharma Sources Insight January 2025
